KORU Medical Systems, Inc. KRMD
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
4/9
Piotroski F — financial health
-0.06
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $41.1M | -$2.6M | $25.6M | — | $17.0M |
| 2024 | $33.6M | -$6.1M | $21.3M | — | $16.8M |
| 2023 | $28.5M | -$13.7M | $16.7M | — | $20.4M |
| 2022 | $27.9M | -$8.7M | $15.4M | — | $31.3M |
| 2021 | $23.5M | -$4.6M | $13.8M | — | $36.5M |
| 2020 | $24.2M | -$1.2M | $14.9M | — | $36.2M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.06 (distress)
- Working capital / assets 0.418
- Retained earnings / assets -1.135
- EBIT / assets -0.105
- Equity / liabilities 1.529
Source: SEC EDGAR filings · CIK 0000704440 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.